tradingkey.logo

Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting On Neurofilament Biomarker Analysis Plan And Confirms Two Additional FDA Meetings

ReutersJun 30, 2025 12:17 PM

Clene Inc. CLNN.O:

  • CLENE PROVIDES REGULATORY UPDATE FOLLOWING CONSTRUCTIVE FDA TYPE-C MEETING ON NEUROFILAMENT BIOMARKER ANALYSIS PLAN AND CONFIRMS TWO ADDITIONAL FDA MEETINGS

  • CLENE INC. - CONFIRMS TWO ADDITIONAL FDA MEETINGS FOR Q3 2025

  • CLENE INC. - ON TRACK FOR ALS NDA SUBMISSION IN Q4 2025

  • CLENE INC. - NFL EAP BIOMARKER ANALYSES TO BE CONDUCTED EARLY Q4 2025

  • CLENE INC. - FDA PROVIDES SUPPORTIVE FEEDBACK ON CLENE'S BIOMARKER ANALYSIS PLAN

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI